BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16762192)

  • 1. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
    Lu YM; Zhang SL; Meng LR; Zhao YY
    Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
    Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Suppression of insulin-like growth factor-1 receptor by RNA interference inhibits cell growth in vitro and induces chemosensitization of HO8910PM cell to cisplatin].
    Gao H; Shi J; Ge SF; DI W
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):45-9. PubMed ID: 18366933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of ovarian cancer growth by small interfering RNA targeting X-linked inhibitor of apoptosis gene].
    Ma JJ; Chen BL; Xin XY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Feb; 42(2):124-8. PubMed ID: 17442189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin].
    Fan W; Zhang HL; Wu XM
    Ai Zheng; 2005 Apr; 24(4):403-7. PubMed ID: 15820060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro gene silencing by siRNA of cyclin D1 on tongue squamous cell carcinoma cell line resistant to cisplatin].
    Zhou XJ; Zhang ZY; Zhang P; Pan HY; Chen WT; Ye DX
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Nov; 41(11):646-9. PubMed ID: 17331354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
    Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
    Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
    Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
    Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of RNA interference for Lon gene silencing on growth and apoptosis of human breast cancer MCF7 cells].
    Xue X; Zhu YF; Mao JP
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):870-4. PubMed ID: 17584658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of small interference RNA on E6, E7 mRNA of human papillomavirus type-18 in cervical cancer cells].
    Wang P; Cui ZM; Luo B; Lin P
    Zhonghua Fu Chan Ke Za Zhi; 2006 Mar; 41(3):190-3. PubMed ID: 16640887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.